864527-95-7Relevant academic research and scientific papers
Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3
Findlay, Alison D.,Foot, Jonathan S.,Buson, Alberto,Deodhar, Mandar,Jarnicki, Andrew G.,Hansbro, Philip M.,Liu, Gang,Schilter, Heidi,Turner, Craig I.,Zhou, Wenbin,Jarolimek, Wolfgang
, p. 9874 - 9889 (2019/11/03)
Lysyl oxidase-like 2 (LOXL2) is a secreted enzyme that catalyzes the formation of cross-links in extracellular matrix proteins, namely, collagen and elastin, and is indicated in fibrotic diseases. Herein, we report the identification and subsequent optimi
CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS
-
Page/Page column 7, (2012/03/12)
This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke, etc.). Recently it was found that activation of GPR119 which is highly expressed in pancreatic beta cells causes glucose dependent insulin secretion and GLP-1 release. Many pharmaceuticals are currently developing GPR119 agonists and herein we disclose alternative GPR119 agonists. Our invention describes GPR119 agonists having structural Formula (I), pharmaceutically acceptable salt or solvate of Formula (I), isomer or prodrug of Formula (I), and combination therapy of Formula (I) with other anti-diabetic drugs like DPP-IV inhibitors and/or insulin sensitizers.
N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS
-
Page/Page column 89, (2009/03/07)
Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control.
MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
-
Page/Page column 236, (2010/02/14)
The present invention provides macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.
